A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
7/24/2026
BreakingCataractGlaucomaRegulationRetinaSurgical
CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444
The Centers for Medicare and Medicaid Services (CMS) on July 14 published its proposed Physician Fee Schedule (PFS) for 2027. Similar to the 2026 schedule, one of two conversion factors will be use...
7/24/2026
BreakingCataractDealsDry EyeGlaucomaLaserRetina
IPG Photonics to Acquire Lumibird Medical for €300 Million
IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...
7/24/2026
AIBreakingPharmaRegulation
Kalshi Offers Betting on Drug Development Timelines and Results
Prediction market Kalshi began on July 16 offering betting on a range of drug development milestones, ranging from clinical trial outcomes and timelines for submissions to US FDA decisions. The New...
7/21/2026
AIMeetingNewsletterRobotics
WOC 2026 Explores How AI Can Expand Access to Eye Care
Artificial intelligence is quickly evolving from a diagnostic tool into a comprehensive clinical assistant with the potential to expand access to eye care worldwide, as emphasized at the 2026 World...
7/24/2026
BreakingGene TherapyRetina
Atsena Will Advance ATSN-401 Gene Therapy Candidate for Stargardt
Atsena Therapeutics announced July 9 that it would advance ATSN-401, a gene therapy candidate for Stargardt disease. Stargardt is an inherited neurodegenerative disease that leads to macular degene...
7/24/2026
BreakingDealsGene TherapyRetina
Ocugen Secures Deal with Roots Pharmaceutical for OCU400 in MENA Region
Ocugen announced July 13 that it had signed a binding term sheet for a license agreement with Kuwait’s Roots Pharmaceutical for exclusive rights to OCU400, Ocugen’s subretinal modifier gene therapy...
7/24/2026
BreakingMyopiaRegulation
Santen Gains Philippines Marketing Approval for Ryjusea (Atropine) for Myopia
Japan’s Santen Pharmaceutical announced June 26 that it had gained marketing approval in the Philippines for preservative-free Ryjusea low-dose atropine drops to slow the progression of pediatric m...
7/24/2026
BreakingCornealRegulation
US FDA Grants RMAT Status to Emmecell’s Corneal Cell Therapy Candidate
Emmecell announced July 7 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to EO2002, the company’s corneal endothelial cell therapy candidate. The RMAT designa...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.